How profitable is Whitehawk Therapeutics Inc. (WHWK)?

In FY 2025 (10-K), WHWK converted $7.1M of revenue into a 89.4% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / WHWK / financials

ZNTL (34) UPB (29) ALXO (44) BBOT (33) ⌘ Pro Terminal →

Whitehawk Therapeutics Inc. (WHWK) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.12 -3.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.09

Whitehawk Therapeutics Inc. (WHWK) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $177.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WHWK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WHWK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Whitehawk Therapeutics Inc. (NASDAQ: WHWK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.12 (-3.70% 1D, market cap $177.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, WHWK ranks #939 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WHWK compare to ZNTL and UPB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WHWK carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 89.4%, and ROIC of -35.0%. By comparison, ZNTL (Zentalis Pharmaceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $175.1M) and UPB (Upstream Bio Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $183.5M). Among the 5-stock peer group, WHWK leads on earnings multiple (N/A) while WHWK leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WHWK?

▼

Per WHWK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422142), Whitehawk Therapeutics Inc. generated $7.1M in revenue (-72.5% YoY), -$20.6M in net income, and -$98.0M in free cash flow against $150.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.09 (-0.86%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WHWK)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (24/100 Composite)

🔍 WHY WHWK SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (29% of score)

Altman Z-Score 3.11 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (25% of score)

FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 39.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.02+5.6% Next Q

Q2 (-2Q)

Grade E$3.19+4.4% Next Q

Q3 (-1Q)

Grade E$3.33-6.3% Next Q

Current

Grade E$3.12-10.9% Hist 90D α

Trajectory: E (16) → E (24)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a WHWK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While WHWK currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.80) and Max Pain ($3.28) forces dealer call-delta covering toward $5.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WHWK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “WHWK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 24%NO 76%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How WHWK Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $24.4M

FY24

Rev $26.0M

FY25

Rev $7.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$7.1M	89.4%	-80%	-$20.6M	-$98.0M	-45%
FY 2024	$26.0M	88.4%	-80%	-$63.7M	-$61.2M	-45%
FY 2023	$24.4M	89.4%	-80%	-$65.8M	-$59.7M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WHWK)

✓Walkthrough of WHWK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

WHWK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.89%▼ DESCENDING CHANNEL

2026-11-04O $3.24H $3.24L $3.12C $3.12VOL 216.1K

RES: $4.84SUP: $2.77SMA50: $3.80SMA200: $3.84

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WHWK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WHWK Butterfly Map → + Track WHWK →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -72.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on WHWK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WHWK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for WHWK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WHWK)

Health Care Rank #939 of 1015 ⚔️ ZNTL vs WHWK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WHWK vs. ZNTL, UPB, ALXO, BBOT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Whitehawk Therapeutics Inc. (WHWK) ranks #939 by composite RQD confidence (24/100, grade E) and #587 by equity capitalization ($177.9M). Within this direct 5-issuer industry benchmark cohort, WHWK leads on earnings valuation at N/A trailing P/E, while WHWK leads on capital efficiency and profitability with -35.0% ROIC and 89.4% gross margin. ALXO currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with WHWK at 24/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
WHWK ACTIVE Whitehawk Therapeutics Inc.	E	24/100	—	89.4%	-35.0%	-3.70%	$177.9M	Benchmark Subject
ZNTL Zentalis Pharmaceuticals Inc.	E	34/100	—	—	-35.0%	-5.61%	$175.1M	/zntl-vs-whwk →
UPB Upstream Bio Inc.	E	29/100	—	—	-35.0%	-1.76%	$183.5M	/upb-vs-whwk →
ALXO ALX Oncology Holdings Inc.	D	44/100	—	—	-35.0%	+12.30%	$171.1M	/alxo-vs-whwk →
BBOT BridgeBio Oncology Therapeutics Inc.	E	33/100	—	—	-35.0%	-11.83%	$185.2M	/bbot-vs-whwk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001422142 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Whitehawk Therapeutics Inc. (WHWK) reported GAAP revenue of $7.1M (-72.5% vs. FY2024 revenue of $26.0M , and -70.7% cumulative change since FY2023) , GAAP net income of -$20.6M, operating cash flow of -$97.4M, and free cash flow of -$98.0M (-60.1% YoY). On the balance sheet, WHWK closed FY2025 with $150.8M in total assets against $0 in total debt (Altman Z-Score: 3.11, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.1M	-$20.6M	-$97.4M	-$98.0M	$150.8M	—
FY2024 (FY)	2024-12-31	$26.0M	-$63.7M	-$59.5M	-$61.2M	$70.3M	—
FY2023 (FY)	2023-12-31	$24.4M	-$65.8M	-$59.7M	-$59.7M	—	—

3. WHWK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WHWK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does WHWK compare to ZNTL and UPB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for WHWK?

Where is WHWK trading relative to its 50-day, 200-day, and 52-week technical levels?

WHWK last traded at $3.12 (-3.70% on volume of 216,121 shares), positioning the stock -17.89% below its 50-day simple moving average ($3.80) and -18.75% below its 200-day simple moving average ($3.84). Across its 52-week range of $1.97 to $5.49, WHWK sits at the 32.7% percentile with a 14-day RSI of 39.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.73 to $3.51).

Direct Sub-Reports: WHWK RQD Cockpit WHWK 12M Forecast WHWK Earnings & Move WHWK Dividends & DRIP WHWK Insiders & 13F WHWK Whale Options WHWK Profit Sankey WHWK News & Why

ROARABLE RATING BRIEF • RQD 24/100 (E) ✓ SEC XBRL & RQD VERIFIED

WHWK — Whitehawk Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Whitehawk Therapeutics Inc. (WHWK) earns a live Roarable RQD composite score of 24/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.12 (-3.70% 1D, market capitalization $177.9M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 89.4%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.11, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Whitehawk Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. FY 2025 revenue was $7.1M, down from $26.0M in FY 2024.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Whitehawk Therapeutics Inc. (WHWK) reported $7.1M in annual revenue (up from $26.0M in FY2024, -72.5% YoY) and -$20.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.4M revenue, -$65.8M net income) through FY2025, WHWK scaled operating cash flow to -$97.4M and free cash flow to -$98.0M, backed by $150.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 24/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.97 – $5.49 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply_chain is NONE and butterfly_links is empty. The source data contains no upstream or downstream dependencies, sector correlation mapping, or bottleneck analysis. A prospective investor should note that the graph cannot identify second-order ripples from this data alone.

Key Question #1: Can WHWK sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $7.1M and free cash flow of -$98.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is WHWK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

WHWK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Whitehawk Therapeutics Inc. (WHWK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WHWK Debate Forum (3) ↓

🟡 MARKET WIRE MarketBeat • 1d ago

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages

MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 1d ago

Form 4 Whitehawk Therapeutics Inc: David James Lennon (Director, CEO) For: 15 September

Investing.com Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Fennec Pharmaceuticals Inc. (FENC) Seasonal Returns Chart

Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 2d ago

Whitehawk Therapeutics (NASDAQ:WHWK) Stock Falls 4.6% - Here's What Happened

MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago

Surrozen, Inc. (SRZN) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 2d ago

High Dividend Yield Stocks for Income

TradingKey report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 2d ago

Whitehawk (WHWK) Stock Price: Up +1.50% Today, Target $3.55 2026-10-28 - VWAP Deviation

https://www.dars.gov.et/ report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 2d ago

Whitehawk Therapeutics, Inc. (WHWK) - What Are Analysts Saying About This Stock?

MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WHWK Bull vs. Bear Conversation Board — What's Your Call at $3.12?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WHWK 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $3.89 (+20.1%)

📌 Pinned Debate

Per the market data, gross margin of 89.4% indicates high revenue-level economics if operating costs can be reduced.

Long WHWK at $3.24 targeting $3.89. Per the market data, gross margin of 89.4% indicates high revenue-level economics if operating costs can be reduced.. Institutional whale score is 4/20 and the risk/reward vs. the $1.97 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@RiskArb_Desk Shorting a 4/20 institutional whale-flow stock at $3.24 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $2.59 (-20.1%)

Spot @ $3.24

Per the SEC financials, free cash flow was negative in every reported period, with FY 2025 FCF at -$98.0M against $37.6M of cash.

I respect the product at Whitehawk Therapeutics Inc., but the stock at $3.24 is a different story. Per the SEC financials, free cash flow was negative in every reported period, with FY 2025 FCF at -$98.0M against $37.6M of cash.. FCF yield is 0.0% and RQD sits at 24/100 (E) — why pay up here when you can wait for next quarter's numbers?